RepliCel Life Sciences (OTC:REPCF) said yesterday that it has developed prototypes of its RCI-02 motorized injection device designed with programmable depth and volume, as well as interchangeable needle head configurations.
The injector was built to deliver an array of substances, including dermal fillers, drugs, cells or biologics intradermally, subcutaneously or intramuscularly.
The company said it hopes to use its functional prototypes to gather feedback from dermatologists, design clinical trials to assess the device and prepare for an anticipated launch in the European market next year.
Replicel reported that one near-term commercial opportunity for RCI-02 is to improve the injection of hyaluronic acid-based dermal fillers.
“As a practicing dermatologist and a co-founder of RepliCel, I am thrilled to see the functioning prototypes,” chief medical officer Dr. Rolf Hoffman said in prepared remarks. “We are excited to begin exploring the clinical applications of this device with our global network of dermatology experts.”
Data from functional testing of the RCI-02 prototypes will help the company prepare an application for CE Mark clearance in the European Union, Replicel said.
“Hitting this milestone confirms we are on track with this product’s commercialization schedule, which involves us getting the device market-ready and in the hands of a commercial partner,” president & CEO, R. Lee Buckler added. “This is the landmark milestone we’ve been waiting for to mature ongoing partnership discussions into negotiations and deal execution.”